FTC Requires Aurobindo Pharma to Shed Four Generics Before Closing Lannett Deal
- June 26, 2026
- Written by AHLA Legal Staff
Aurobindo Pharma Limited must divest four generic drug products before moving ahead with its $250 million acquisition of Philadelphia-based Lannett Company Inc. under a proposed consent order the Federal Trade Commission (FTC) announced June 18.
ARTICLE TAGS
You must be logged in to access this content.